12:00 AM
 | 
Mar 25, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Bretaris/Eklira Genuair aclidinium bromide regulatory update

Germany's Federal Joint Committee (G-BA) said Bretaris/Eklira Genuair aclidinium bromide from Almirall has "no additional benefit" over Spiriva HandiHaler tiotropium for chronic obstructive pulmonary disease (COPD). The decision is in line with a preliminary benefit assessment from the Institute for Quality and Efficiency in Health Care (IQWiG)...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >